U.S. markets close in 1 hour 44 minutes
  • S&P 500

    4,280.85
    -18.85 (-0.44%)
     
  • Dow 30

    33,445.07
    -221.27 (-0.66%)
     
  • Nasdaq

    13,199.12
    -2.15 (-0.02%)
     
  • Russell 2000

    1,782.93
    -11.39 (-0.63%)
     
  • Crude Oil

    90.71
    -1.00 (-1.09%)
     
  • Gold

    1,866.60
    -12.00 (-0.64%)
     
  • Silver

    22.41
    -0.34 (-1.48%)
     
  • EUR/USD

    1.0573
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    4.5670
    -0.0300 (-0.65%)
     
  • GBP/USD

    1.2195
    -0.0011 (-0.09%)
     
  • USD/JPY

    149.4160
    +0.1420 (+0.10%)
     
  • Bitcoin USD

    26,774.21
    -443.09 (-1.63%)
     
  • CMC Crypto 200

    576.83
    -1.93 (-0.33%)
     
  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     
  • Nikkei 225

    31,857.62
    -14.90 (-0.05%)
     

Why CRISPR Therapeutics Just Became an Even Better Buy

Why CRISPR Therapeutics Just Became an Even Better Buy

CRISPR Therapeutics (NASDAQ: CRSP) is a growth stock with a lot of long-term potential. Its gene-editing business could be about to take off if exa-cel obtains approval from the Food and Drug Administration (FDA). What makes gene-editing therapies potential game changers in the healthcare industry is that they have the potential to revolutionize treatment options for diseases.